SCHEDULE: Bellevue Group Discloses Yarrow Bioscience Stake

Bellevue Group AG and its subsidiary Bellevue Asset Management AG have reported beneficial ownership of 10.6% of Yarrow Bioscience, Inc. common stock.

Summary

• Bellevue Group AG and its subsidiary Bellevue Asset Management AG (BAM AG) have jointly filed a Schedule 13G.
• They collectively beneficially own 1,000,000 shares of Yarrow Bioscience, Inc. common stock.
• This represents 10.6% of the class of securities outstanding.
• The percentages are based on 9,437,693 shares outstanding as of September 14, 2026, following an equity offering.
• Bellevue Group AG is a Swiss holding company, and BAM AG is its wholly-owned Swiss subsidiary.
• Both entities are registered as investment advisors or similar financial institutions.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial performance data.

Positives

• Significant ownership stake (10.6%) by Bellevue Group AG and BAM AG indicates confidence or strategic interest in Yarrow Bioscience.
• The filing is current and reflects recent shareholding information.
• The reporting entities are regulated financial institutions, suggesting a professional approach to investment.

Negatives

• The filing does not provide any new financial performance data or operational updates for Yarrow Bioscience.
• It is a disclosure of existing ownership, not an announcement of new investment or strategic partnership.

Risks

• As a Schedule 13G filing, it indicates passive investment, meaning Bellevue Group AG and BAM AG do not intend to influence or control Yarrow Bioscience's management or policies.
• The investment is subject to market fluctuations and the overall performance of Yarrow Bioscience.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Yarrow Bioscience's future performance.

Management Comments

• The percentages of beneficial ownership contained herein are based on 9,437,693 shares of Common Stock outstanding as of September 14, 2026 (after giving effect to the closing of an equity offering by the Issuer on such date), as reported by the Issuer in its Prospectus Supplement filed with the SEC on September 11, 2026.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Bellevue Group AG and BAM AG are substantial, passive investors in Yarrow Bioscience, a biotechnology company.

Stakeholder Impact

• Shareholders of Yarrow Bioscience, Inc. are informed of a significant passive ownership stake held by Bellevue Group AG and BAM AG.
• The passive nature of the investment suggests no immediate change in corporate control or strategy is being driven by these holders.

Next Steps

• Bellevue Group AG and BAM AG will continue to hold their shares in Yarrow Bioscience, Inc.
• Further filings may be required if their beneficial ownership changes significantly.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Yarrow Bioscience, Bellevue Group AG, Bellevue Asset Management AG, Investment Holding, Common Stock, Switzerland